{"id":70102,"date":"2026-07-16T16:34:20","date_gmt":"2026-07-16T08:34:20","guid":{"rendered":"https:\/\/flcube.com\/?p=70102"},"modified":"2026-07-16T16:34:22","modified_gmt":"2026-07-16T08:34:22","slug":"hengrui-pharmaceuticals-secures-dual-nmpa-approvals-for-hrs-8797-atopic-dermatitis-drug-and-hrs-8829-stroke-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70102","title":{"rendered":"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced today that <strong>HRS-8797 Tablets<\/strong> and <strong>HRS-8829 Concentrated Solution for Injection<\/strong> have received clinical trial approvals from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>. The dual approvals advance Hengrui&#8217;s innovative pipeline in dermatology and neurology with potentially first-in-class assets.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestones-key-details\" class=\"wp-block-heading\">Regulatory Milestones | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>HRS-8797<\/th><th>HRS-8829<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Category 1 innovative drug<\/td><td>Small-molecule drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Atopic dermatitis<\/td><td>Acute ischemic stroke (combination with Edaravone)<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Independently developed by Hengrui<\/td><td>Small-molecule candidate<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>No similar drug approved globally<\/td><td>Phase 1 monotherapy ongoing<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>NMPA (China)<\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 16, 2026<\/td><td>July 16, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-hrs-8797-first-in-class-atopic-dermatitis-candidate\" class=\"wp-block-heading\">HRS-8797: First-in-Class Atopic Dermatitis Candidate<\/h2>\n\n\n\n<h3 id=\"h-innovation-profile\" class=\"wp-block-heading\">Innovation Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification:<\/strong> Category 1 drug (first-in-class designation in China)<\/li>\n\n\n\n<li><strong>Development:<\/strong> Independently developed by Hengrui Pharmaceuticals<\/li>\n\n\n\n<li><strong>Global Uniqueness:<\/strong> No similar drug approved for marketing worldwide<\/li>\n\n\n\n<li><strong>Therapeutic Area:<\/strong> Atopic dermatitis \u2013 chronic inflammatory skin condition<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-opportunity\" class=\"wp-block-heading\">Market Opportunity<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Atopic dermatitis affects approximately <strong>15-20% of children and 1-3% of adults<\/strong> globally, with significant unmet need for safer, more effective treatments. Current therapies include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Topical corticosteroids<\/strong> with long-term safety concerns<\/li>\n\n\n\n<li><strong>Biologics<\/strong> (e.g., dupilumab) with high cost and injection requirements<\/li>\n\n\n\n<li><strong>JAK inhibitors<\/strong> with safety monitoring requirements<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">HRS-8797&#8217;s potential first-in-class status positions it to address limitations of existing therapies while offering a novel mechanism of action for this prevalent condition.<\/p>\n\n\n\n<h2 id=\"h-hrs-8829-novel-stroke-combination-therapy\" class=\"wp-block-heading\">HRS-8829: Novel Stroke Combination Therapy<\/h2>\n\n\n\n<h3 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approved Indication:<\/strong> Combination with Edaravone Injection for acute ischemic stroke<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> Phase 1 monotherapy trial ongoing<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Enhanced neuroprotection through complementary mechanisms<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Comprehensive preclinical studies demonstrated robust neuroprotective effects:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neurological Function:<\/strong> Significant reduction in neurological function scores<\/li>\n\n\n\n<li><strong>Infarction Reduction:<\/strong> Decreased cerebral infarction volume<\/li>\n\n\n\n<li><strong>Edema Control:<\/strong> Reduced cerebral edema formation<\/li>\n\n\n\n<li><strong>Anti-inflammatory Effects:<\/strong> Inhibition of inflammatory cytokine expression<\/li>\n\n\n\n<li><strong>Neuroprotection:<\/strong> Ameliorated reduction in neuronal count<\/li>\n\n\n\n<li><strong>Anti-apoptotic Activity:<\/strong> Suppressed neuronal apoptosis<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-significance\" class=\"wp-block-heading\">Therapeutic Significance<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Acute ischemic stroke represents a <strong>critical unmet medical need<\/strong> with limited treatment windows and modest efficacy of current interventions. The combination approach with Edaravone\u2014a free radical scavenger already approved for stroke\u2014could provide synergistic neuroprotection through:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oxidative stress reduction<\/strong> (Edaravone mechanism)<\/li>\n\n\n\n<li><strong>Inflammation modulation and neuronal protection<\/strong> (HRS-8829 mechanism)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-hengrui-pharmaceuticals\" class=\"wp-block-heading\">Strategic Implications for Hengrui Pharmaceuticals<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">These dual approvals reinforce Hengrui&#8217;s position as a <strong>leading Chinese innovative pharmaceutical company<\/strong>:<\/p>\n\n\n\n<h3 id=\"h-pipeline-diversification\" class=\"wp-block-heading\">Pipeline Diversification<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Expansion:<\/strong> Entry into dermatology and neurology beyond core oncology focus<\/li>\n\n\n\n<li><strong>Modality Diversity:<\/strong> Both small molecule and potentially novel mechanism drugs<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> First-in-class potential for international development opportunities<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-innovation-validation\" class=\"wp-block-heading\">Innovation Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Capability:<\/strong> Demonstrates successful internal drug discovery and development<\/li>\n\n\n\n<li><strong>Regulatory Expertise:<\/strong> Efficient navigation of NMPA approval processes<\/li>\n\n\n\n<li><strong>Clinical Strategy:<\/strong> Strategic combination approaches for complex diseases<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-potential\" class=\"wp-block-heading\">Commercial Potential<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atopic Dermatitis Market:<\/strong> Global market projected to reach <strong>$10+ billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Stroke Therapeutics:<\/strong> Massive addressable population with high unmet need<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> First-in-class and combination therapy positioning supports premium pricing<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The simultaneous advancement of two distinct therapeutic programs showcases Hengrui&#8217;s <strong>robust pipeline management capabilities<\/strong> and strategic focus on high-value specialty therapeutic areas with significant unmet medical needs.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-atopic-dermatitis\" class=\"wp-block-heading\">Atopic Dermatitis<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">HRS-8797 enters a competitive but growing market dominated by biologics and JAK inhibitors, but its <strong>first-in-class potential<\/strong> and oral administration could provide significant differentiation.<\/p>\n\n\n\n<h3 id=\"h-acute-ischemic-stroke\" class=\"wp-block-heading\">Acute Ischemic Stroke<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The stroke therapeutics market has seen limited innovation since the introduction of tPA and mechanical thrombectomy. HRS-8829&#8217;s <strong>combination approach with established Edaravone<\/strong> offers a pragmatic development pathway with potential for rapid clinical adoption.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260716_THM1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260716_THM1.\"><\/object><a id=\"wp-block-file--media-b6f0b819-57fa-4391-b26b-3a6aad07ed70\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260716_THM1.pdf\">600276_20260716_THM1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260716_THM1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b6f0b819-57fa-4391-b26b-3a6aad07ed70\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,2586,4228,852],"class_list":["post-70102","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and HRS-8829 Concentrated Solution for Injection have received clinical trial approvals from China&#039;s National Medical Products Administration (NMPA). The dual approvals advance Hengrui&#039;s innovative pipeline in dermatology and neurology with potentially first-in-class assets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70102\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and HRS-8829 Concentrated Solution for Injection have received clinical trial approvals from China&#039;s National Medical Products Administration (NMPA). The dual approvals advance Hengrui&#039;s innovative pipeline in dermatology and neurology with potentially first-in-class assets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70102\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T08:34:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T08:34:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70102#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70102\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy\",\"datePublished\":\"2026-07-16T08:34:20+00:00\",\"dateModified\":\"2026-07-16T08:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70102\"},\"wordCount\":591,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70102#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70102\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70102\",\"name\":\"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T08:34:20+00:00\",\"dateModified\":\"2026-07-16T08:34:22+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and HRS-8829 Concentrated Solution for Injection have received clinical trial approvals from China's National Medical Products Administration (NMPA). The dual approvals advance Hengrui's innovative pipeline in dermatology and neurology with potentially first-in-class assets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70102#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70102\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70102#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and HRS-8829 Concentrated Solution for Injection have received clinical trial approvals from China's National Medical Products Administration (NMPA). The dual approvals advance Hengrui's innovative pipeline in dermatology and neurology with potentially first-in-class assets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70102","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and HRS-8829 Concentrated Solution for Injection have received clinical trial approvals from China's National Medical Products Administration (NMPA). The dual approvals advance Hengrui's innovative pipeline in dermatology and neurology with potentially first-in-class assets.","og_url":"https:\/\/flcube.com\/?p=70102","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T08:34:20+00:00","article_modified_time":"2026-07-16T08:34:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70102#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70102"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy","datePublished":"2026-07-16T08:34:20+00:00","dateModified":"2026-07-16T08:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70102"},"wordCount":591,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70102#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70102","url":"https:\/\/flcube.com\/?p=70102","name":"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T08:34:20+00:00","dateModified":"2026-07-16T08:34:22+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and HRS-8829 Concentrated Solution for Injection have received clinical trial approvals from China's National Medical Products Administration (NMPA). The dual approvals advance Hengrui's innovative pipeline in dermatology and neurology with potentially first-in-class assets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70102#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70102"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70102#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70102"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70102\/revisions"}],"predecessor-version":[{"id":70105,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70102\/revisions\/70105"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}